Table 1 Demographic and baseline clinical characteristics of the study sample (n = 3685)
GP down-referred | Clinic A controls | Clinic B controls | Total | |
|---|---|---|---|---|
373 (10.1) | 2599 (70.5) | 713 (19.4) | 3685 (100.0) | |
n (%) | n (%) | n (%) | n (%) | |
Sex | ||||
Female | 258 (69.2) | 1717 (66.1) | 463 (64.9) | 2438 (66.2) |
Male | 115 (30.8) | 882 (33.9) | 250 (35.1) | 1247 (33.8) |
Age at down-referral/eligibility (years) Median (IQR) | 40.6 (35.9–47.2) | 38.9 (33.8–44.9) | 39.7 (33.3–47.4) | 39.3 (33.9–45.7) |
18–29.99 | 21 (5.6) | 301 (11.6) | 109 (15.3) | 431 (11.7) |
30–39.99 | 150 (40.2) | 1117 (43.0) | 251 (35.2) | 1518 (41.2) |
40–49.99 | 133 (35.7) | 855 (32.9) | 224 (31.4) | 1212 (32.9) |
50+ | 69 (18.5) | 326 (12.5) | 129 (18.1) | 524 (14.2) |
Nationality | ||||
South African | 316 (84.7) | 2281 (87.8) | 696 (97.6) | 3293 (89.4) |
Non-South African | 57 (15.3) | 318 (12.2) | 17 (2.4) | 392 (10.6) |
Education level | ||||
Primary school or less | 58 (15.5) | 386 (14.9) | 216 (30.3) | 660 (17.9) |
Some secondary school | 105 (28.2) | 685 (26.4) | 28 (3.9) | 818 (22.2) |
> =Grade 12 | 180 (48.3) | 1107 (42.6) | 433 (60.7) | 1720 (46.7) |
Missing | 30 (8.0) | 421 (16.2) | 36 (5.0) | 487 (13.2) |
Employment status | ||||
Employed | 238 (63.8) | 1430 (55.0) | 209 (29.3) | 1877 (50.9) |
Unemployed | 130 (34.9) | 1125 (43.3) | 472 (66.2) | 1727 (46.9) |
Missing | 5 (1.3) | 44 (1.7) | 32 (4.5) | 81 (2.2) |
Time on ART at down-referral/eligibility (years) Median (IQR) | 4.2 (2.7–6.3) | 3.0 (1.9–5.0) | 2.1 (1.5–3.7) | 3.0 (1.8–4.9) |
1–2.9 year | 104 (27.9) | 1281 (49.3) | 480 (67.3) | 1865 (50.6) |
3–4.9 years | 111 (29.8) | 678 (26.1) | 136 (19.1) | 925 (25.1) |
> = 5 years | 158 (42.4) | 640 (24.6) | 97 (13.6) | 895 (24.3) |
Guideline year of ART initiation | ||||
2004–2010 | 205 (55.0) | 1828 (70.3) | 361 (50.6) | 2394 (65.0) |
2011–2014 | 168 (45.0) | 771 (29.7) | 352 (49.4) | 1291 (35.0) |
Baseline CD4 (cells/μl) | ||||
250–349.9 | 152 (40.8) | 679 (26.1) | 196 (27.5) | 1027 (27.9) |
350–499.9 | 137 (36.7) | 854 (32.9) | 228 (32.0) | 1219 (33.1) |
> =500 | 84 (22.5) | 1066 (41.0) | 289 (40.5) | 1439 (39.1) |
Baseline VL (copies/ml) | ||||
< 50 | 297 (79.6) | 1466 (56.4) | 475 (66.7) | 2238 (60.8) |
50–199 | 61 (16.4) | 698 (26.9) | 151 (21.2) | 910 (24.7) |
200–399 | 15 (4.0) | 434 (16.7) | 86 (12.1) | 535 (14.5) |
Baseline Haemoglobin (g/dL) Med (IQR) | 14.0 (13.0–14.8) | 13.9 (12.9–15.0) | 14.0 (13.0–14.9) | 13.9 (12.9–14.9) |
Baseline BMI (kg/m2) | ||||
Normal | 241 (64.6) | 993 (38.2) | 291 (40.8) | 1525 (41.4) |
Overweight | 82 (22.0) | 593 (22.8) | 158 (22.2) | 833 (22.6) |
Obese | 46 (12.3) | 350 (13.5) | 101 (14.2) | 497 (13.5) |
Missing | 4 (1.1) | 663 (25.5) | 163 (22.9) | 830 (22.5) |
ART regimen | ||||
TDF + 3TC/FTC + EFV/NVP | 172 (46.1) | 754 (29.4) | 342 (48.0) | 1268 (34.8) |
AZT + 3TC + EFV/NVP | 18 (4.8) | 152 (5.9) | 24 (3.4) | 194 (5.3) |
d4T + 3TC + EFV/NVP | 183 (49.1) | 1656 (64.6) | 347 (48.7) | 2186 (59.9) |
Comorbidities in the 12 month follow-up | ||||
No | 366 (98.1) | 2529 (97.3) | 694 (97.3) | 3589 (97.4) |
Yes | 7 (1.9) | 70 (2.7) | 19 (2.7) | 96 (2.6) |
12 month Retention | ||||
Alive and in care | 331 (88.7) | 1736 (66.8) | 367 (51.5) | 2434 (66.1) |
LTFU | 42 (11.3) | 83 (3.2) | 175 (24.5) | 300 (8.1) |
Deceased | 0 | 26 (1.0) | 7 (1.0) | 33 (0.9) |
Transferred out | 0 | 754 (29.0) | 164 (23.0) | 918 (24.9) |
12 month-VL suppression (< 50 copies/mL) | ||||
Unsuppressed | 119 (31.9) | 967 (37.2) | 260 (36.5) | 1346 (36.5) |
Suppressed | 228 (61.1) | 934 (35.9) | 373 (52.3) | 1535 (41.7) |
Missing | 26 (7.0) | 698 (26.9) | 80 (11.2) | 804 (21.8) |